Arcus Biosciences, Inc.

191 articles about Arcus Biosciences, Inc.

• Arcus Biosciences Announces New Employment Inducement Grants - Jan 26, 2021

  1/26/2021

  Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 165,300 shares of the Company’s common stock at an exercise price per share of $38.19, which was the closing price on January 25, 2021.

• 

  Clinical Catch-Up: January 11-15

  1/18/2021

  The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.

• Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

  1/15/2021

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).

• Arcus Biosciences Announces New Employment Inducement Grants - Jan 12, 2021

  1/12/2021

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021.

• Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium

  1/11/2021

  - Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy - Additional data, as of a cut-off date of December 9, 2020, to be presented at ASCO-GI on January 15 th

• Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors

  1/6/2021

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also serve as a member of Arcus’s Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success

• Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

  12/10/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, today announced an expansion of their existing strategic relationship under which the parties will discover anti-CD39 antibodies using WuXi Bio’s proprietary technology

• Arcus Biosciences Announces New Employment Inducement Grants - Dec 10, 2020

  12/10/2020

  Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted twenty new employees options to purchase a total of 310,500 shares of the Company’s common stock at an exercise price per share of $29.93, which was the closing price on December 8, 2020.

• Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference

  11/18/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:30 a.m. Eastern Time.

• Arcus Biosciences Announces New Employment Inducement Grants - Nov 10, 2020

  11/10/2020

  Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 343,000 shares of the Company’s common stock at an exercise price per share of $21.53, which was the closing price on November 9, 2020.

• Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates

  11/5/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates.

• Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC

  10/29/2020

  Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi ® in Stage III NSCLC - Collaboration Further Strengthens Arcus’s Position at the Forefront of the Anti-TIGIT Field and Leverages AstraZeneca’s Leadership in the Curative-Intent Stage III NSCLC Setting - Registrational Trial for Domvanalimab plus Imfinzi Expected to Begin in 2021 - Further Builds on the Arcus-Gilea

• 

  AstraZeneca and Arcus Biosciences Pair Assets in NSCLC Study

  10/29/2020

  Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.

• Arcus Biosciences Announces New Employment Inducement Grants - Oct 08, 2020

  10/8/2020

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seventeen new employees options to purchase a total of 559,000 shares of the Company’s common stock at an exercise price per share of $19.20, which was the closing price on October 8, 2020.

• Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer

  10/1/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarrett has rejoined Arcus as Chief Operating Officer with responsibility for Arcus’s commercial and general & administrative organizations, including finance and human resources.

• Arcus Biosciences Announces New Employment Inducement Grants - Sep 10, 2020

  9/10/2020

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 120,500 shares of the Company’s common stock at an exercise price per share of $20.71, which was the closing price on September 8, 2020.

• Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences

  8/27/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences:

• Arcus Biosciences Announces New Employment Inducement Grants - Aug 11, 2020

  8/11/2020

  Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 135,900 shares of the Company’s common stock at an exercise price per share of $22.96, which was the closing price on August 10, 2020.

• Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates

  8/6/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates.

• Arcus Biosciences Announces New Employment Inducement Grant

  8/4/2020

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on July 7, 2020, the company made an inducement grant to Robert C. Goeltz II, the newly-appointed Chief Financial Officer of Arcus